Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, University of Oxford Collaborate on Diagnostics, Therapy for Colorectal Cancer

NEW YORK, Sept. 22 (GenomeWeb News) - GE Healthcare and the Universityof Oxfordwill collaborate to study the pathology of colorectal cancer to improve early diagnosis and therapy, the company said today.


Under the two-year partnership, GE Healthcare will contribute its expertise in genomic and information technologies, while the Universityof Oxfordwill provide clinical data as well as medical and research expertise.


The partners will focus on improved cancer staging using both imaging and genomic pathology, therapy selection and efficacy assessment, and treatment monitoring.


Details on the technologies to be used were not available from the company statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.